Empyema, Pleural

4

Review clinical trials related to Empyema, Pleural. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Once Daily Intrapleural Enzyme Therapy in Complicated Parapneumonic Effusion or Empyema

The goal of this clinical trial is to find out if giving certain medications once a day works just as well as giving them twice a day to treat infections around the lungs (called pleural infections). These medications-tissue plasminogen activator (tPA) and deoxyribonuclease (DNase)-are placed through a chest tube into the space between the lung and the chest wall to help clear out the infection. The investigators are trying to learn: * Does using the medicine once a day work just as well as using it twice a day? * Are there any differences in outcomes between patients who get the medicine once a day versus twice a day? * Does more or less fluid remain in the chest (seen on a chest x-ray) depending on how often the medicine is given? Participants will: * Have an infection around their lung and will already be getting normal hospital care, including a chest tube to drain the infected fluid around their lung. * Be asked to give permission to join the study. * Be randomly chosen (like flipping a coin) to get the medications either once a day or twice a day through the chest tube.

Participants needed: 270
Trial details
Phase: Phase 4Age: 18+Biological sex: AllType: InterventionalSponsor: University of North Carolina, Chapel HillUpdated: May 19, 2026Locations: 6
Eligibility criteria

Written informed consent obtained from patient or patient's legally authorized r... [+4]

Known pregnancy or lactating females [+8]

Status: Not yet recruiting

Flush, Lyse, Operate

The goal of this observational study is to learn if saline results in improvement for patients with infection of their plerual space. The main question it aims to answer is: What is the time to chest tube removal? Do these patients after need to escalate to fibrinolytics? Do these patients after need to escalate to surgery? Participants will: * Receive receive saline into their pleural space through an existing chest tube * If they fail to improve, which will be determined by fluid size after treatment or signs of persistent infection, they will receive fibrynolytics through an existing chest tube * If they fail to improve, which will be determined by fluid size after treatment or signs of persistent infection, they will be referred to surgery.

Participants needed: 30
Trial details
Phase: Phase 4Age: 18+Biological sex: AllType: InterventionalSponsor: Dartmouth-Hitchcock Medical CenterUpdated: May 18, 2026Locations: 1
Eligibility criteria

Age 18+ [+2]

Age < 18 years [+6]

Status: Recruiting

Chest Drain Regular Flushing in Complicated Parapneumonic Effusions and Empyemas

Infections of the pleural space are common, and patients require antibiotics and chest drain placement to evacuate the chest from the infected fluid. Chest drains can get blocked by the drainage fluid and material. For this reason, it is thought that flushing the chest drain with saline solution, can help maintain the patency of the tube. This proposed study will evaluate the impact of regular chest drain flushing on the length of time to chest tube removal and total hospitalization as well as improvement in chest imaging and the need for additional interventions on the infected space.

Participants needed: 96
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Vanderbilt University Medical CenterUpdated: Feb 20, 2026Locations: 5
Eligibility criteria

Patients with complicated parapneumonic pleural effusion and empyema requiring c... [+1]

Patients who have surgical tubes that can't accommodate a three-way stopcock. [+5]

Status: Recruiting

Complicated Pneumonia (CP) in Children in South-East Europe

This retrospective observational study aims to evaluate clinical course of complicated community acquired pneumonia in children, particularly focusing on necrotizing pneumonia cases, as well as determination of etiological agents (viruses and bacteria) and its association to severity and outcomes of the disease. Furthermore, therapeutic approach, complications, short-term and long-term outcomes and the prevention of the disease are to be assessed. The study will encompass data from pediatric centers in the South-East Europe willing to participate in the study, encompassing ten-year period of time.

Participants needed: 300
Trial details
Age: 1-18Biological sex: AllType: ObservationalSponsor: Aleksandar SovticUpdated: Oct 26, 2024Locations: 1
Eligibility criteria

Children aged 1 month to 18 years of age [+2]

Children with increased risk for severe lung infections (cystic fibrosis, primar... [+1]